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Utilization characteristics from a managed commercial health
plan with a 3-tier beneﬁt design were used for comparison. Pre-
scription utilization data statistics such as per member per month
costs and utilization and types of drug used were calculated. The
top ﬁve therapeutic classes ranked by drug cost per member per
month were also identiﬁed and compared. RESULTS: Mail order
penetration was 5.9% with Medicare and 3.6% for commercial
businesses. Mean age of pharmacy utilizers was 73.1 and 50.6
years in Medicare and commercial business, respectively. Generic
utilization was lower for mail order versus retail pharmacies
(46.9% and 54.8% for Medicare and 34.8% and 46.2% for
commercial business, respectively). Prescription volume was 30.8
and 9.4 per member per year in Medicare and commercial busi-
ness, respectively. Mean ingredient cost was lower in Medicare
plans ($43.79 versus $56.68 in commercial business), while
mean copay was higher in Medicare plans ($27.92 versus $20.08
in commercial business). The top therapeutic classes, as ranked
by ingredient cost per member per month, were similar for both
Medicare and commercial businesses. For Medicare business, the
top classes were antihyperlipidemics, antihypertensives, ulcer
drugs, and antidiabetic agents. For commercial business the top
classes were antihyperlipidemics, ulcer drugs, antidepressants,
and antidiabetic agents. CONCLUSIONS: Prescription utiliza-
tion patterns and drug mix for members in Medicare programs
and commercial health plans differed, mainly driven by beneﬁt
design and coverage policy. Understanding of these differences
are essential to effective Medicare pharmacy program design.
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CONTENT ANALYSIS OF PRINT DIRECT TO CONSUMER
DRUG ADVERTISEMENTS TO DETERMINE NUMBER AND
SPECIFICITY OF RISK STATEMENTS
Valluri S
Ohio State University, Columbus, OH, USA
OBJECTIVE: The objective of the current study is to determine
number and the speciﬁcity of risk factors (side effects, speciﬁc
side effects, contra indications, total number of sentences) dis-
closed in a typical direct-to-consumer print advertisement pub-
lished in 2002. METHODS: Content analysis is a research
technique for the systematic classiﬁcation and description of
communication content to certain usually predetermined cate-
gories. All product speciﬁc prescription drug advertisements
appearing in seven consumer magazines from January 2002 to
December 2002 were collected. The sampling of magazines was
purposive. The magazines were selected based upon their circu-
lation and appeal. All the four variables were deﬁned explicitly.
Side effects were deﬁned as any unwarranted secondary and
adverse effects of the drug. Speciﬁc side effects were deﬁned as
those side effects, which were stressed upon, and where more
information was provided. Contraindications were deﬁned as
statements that contraindicate the use of the advertised drug in
speciﬁc populations or situations. The total number of sentences
was deﬁned as the total number of sentences in the print adver-
tisement that contained any of the side effects, speciﬁc side effects
or contraindications. Judges were trained to determine the valid-
ity of operational guidelines. Cohen’s Kappa was used to deter-
mine inter-rater agreement. Each brand name drug advertisement
served as the unit of analysis. Descriptive statistics were the
primary tool for analytical procedures. RESULTS: A total of 349
advertisements were identiﬁed which represented 40 distinct
brand drugs. There was an average of 4.6 side effects per adver-
tisement. Of these, 0.7 speciﬁc side effects were mentioned per
advertisement. Each advertisement contained an average of 1.7
contraindications and 2.55 sentences. CONCLUSION: Adver-
tisements contained only an average of 2.55 risk statements. The
average number of side effects disclosed in a typical advertise-
ment is less than ﬁve. More than half of the advertisements did
not mention speciﬁc side effects.
PHP38
AN ASSESSMENT OF THE EFFECT OF DEMOGRAPHICAL AND
SOCIOLOGICAL FACTORS ON INDIVIDUAL RESPONSE TO
DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION
DRUGS
Makin C, Murawski M
Purdue University, West Lafayette, IN, USA
OBJECTIVES: The objective of this study was to investigate the
factors inﬂuencing the relationship between Health Locus of
Control (HLC) and consumer responsiveness to Direct-to-Con-
sumer advertising (RDTCA) of generic and brand name pre-
scription drugs. This study was intended to provide a framework
to aid in the promotion of generic utilization by consumers and
better targeting of consumers by DTC advertisements in a more
cost-efﬁcient manner, thereby reducing health care expenditure.
METHODS: Direct-mail survey was employed for the purpose
of this study, and questionnaires were sent to a simple random
sample of 900 individuals taken from the entire population of
the United States. The survey was designed according to
Dillman’s Total Design Method, and consisted of several vali-
dated scales, such as the Wallston multidimensional HLC scale,
the Health Value scale by Lau et al, some items seeking to estab-
lish consumer RDTCA, and demographic items. RESULTS: A
net response rate of 47.33% was obtained. Regression tech-
niques and ANOVA were the primary statistical tests employed
to address the research questions. The results established that
RDTCA of brand name prescription drugs was signiﬁcantly
related to External HLC orientation, educational level, income,
gender, race and presence of health insurance. The analysis also
showed the existence of statistically signiﬁcant relationships
between RDTCA of generics and educational level, income,
gender and presence of health insurance. The study suggests that
RDTCA of prescription drugs decreases as the level of both edu-
cation and household income increases, and that females are
more likely to respond to DTC advertising. CONCLUSIONS:
Consumer responsiveness to DTC advertising of prescription
drugs can serve as the basis for well-directed DTC campaigns at
target populations. The results provide several variables that can
be used as the basis for market segmentation, which can be useful
for DTC advertising of both brand name and generic prescrip-
tion drugs.
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1University of Arizona,Tucson, AZ, USA; 2University of Texas at Austin,
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OBJECTIVE: The objective of this research was to examine the
relationship between ﬁnancial valuation and both ﬁrm- and
industry-speciﬁc measures of technological change for ﬁrms
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whose core competencies involved the research and development
(R&D) of pharmaceutical, medical, or biotechnological innova-
tion. METHODS: Regression methods were utilized for a sample
of 50 highly-innovative parent companies from 1985 to 1998.
Dependent variables included stock market capitalization and
returns. Independent variables included, but were not limited to,
risk, patent activity, new molecular entity (NME) approvals, and
R&D expenditures. RESULTS: Semi-elasticities of market capi-
talization with respect to ﬁrm-level determinants of innovative
activity generally differed as a function of ﬁrm size. Measures of
innovative output, including patents and NMEs, were signiﬁcant
only for the larger ﬁrm classiﬁcations, while R&D expenditures
were signiﬁcant for all group classiﬁcations. Smaller companies
received higher relative valuations per million dollars spent on
R&D than their larger rivals, and large ﬁrms received higher val-
uations based upon a one percent increase in R&D budgets. The
analysis of stock market returns indicated that larger companies
received returns, which were more consistently positive and less
volatile, even though mean returns between groups were not sta-
tistically different. Accounting for the skewed nature of these
data, the median returns differed substantially based upon ﬁrm
size. The multivariate analysis of these returns did not reveal a
trend that was consistent with either R&D inputs or outputs.
CONCLUSIONS: Considerable differences in the valuation
makeup of companies were observed between ﬁrm size. Dimin-
ishing semi-elasticities existed with respect to increasing ﬁrm size
for many of the variables in the econometric analysis. Numer-
ous phenomena appeared to impact stock market returns, 
indicating challenges in the appropriate valuation of companies
concerning future R&D beneﬁts, or that positive returns were
not guaranteed even though overall R&D expenditures or inno-
vative output increased.
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POST-LAUNCH STUDIES—WHAT IS DESIRABLE,
WHAT IS FEASIBLE?
Mason A1, Drummond MF1,Towse A2
1University of York,York, United Kingdom; 2Ofﬁce of Health
Economics, London, United Kingdom
OBJECTIVE: Given the increased interest in conducting phar-
macoeconomics and outcomes studies post-launch, the objective
of this study was to explore the desirability and feasibility of dif-
ferent types of studies. METHODS: The published literature on
post-launch studies was reviewed and the recommendations for
further research made by the National Institute for Clinical
Excellence (NICE) in the UK were analysed. In addition, global
heads of pharmacoeconomics and outcomes research (PE/OR) in
major pharmaceutical companies were surveyed to ascertain
their experience in conducting studies post-launch and the prob-
lems encountered. RESULTS: In the ﬁrst 46 technology appraisal
of drugs conducted by NICE, recommendations for further
research included head-to-head studies of the new drug with rel-
evant alternatives (39% of appraisals); better information on
impacts on quality of life (43%); longer term evidence on com-
pliance, adverse events or maintenance of clinical effect (41%);
study of the drug in relevant patient sub-groups (33%); and
understanding the most cost-effective use of the drug in routine
practice (43%). The survey of heads of PE/OR departments
revealed a wide variety of experience with conducting post-
launch studies. The problems identiﬁed included the need for
large sample sizes, difﬁculties in ﬁnancing studies and the
unfavourable risk-beneﬁt of some studies from a commercial per-
spective. CONCLUSIONS: Whilst it is desirable to conduct
pharmacoeconomics and outcomes research post-launch, those
bodies recommending such studies should pay more attention to
the practical and methodological challenges raised by certain
study designs.
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PARALLEL TRADE OF PHARMACEUTICALS AS A 
COST-CONTAINMENT MEASURE-ANALYSIS OF THE 
ISRAELI EXPERIENCE
Eldar-Lissai A1, Shvarts S2, Goldberg A2, Shani S2
1University of Rochester, Rochester, NY, USA; 2Ben-Gurion University
of the Negev, Israel
The Israeli Law enabling parallel import of pharmaceuticals was
implemented in January 2001. Prior to its legislation there was
only one exclusive importer for each pharmaceutical product,
imported directly from the manufacturer. Parallel import enables
the importation of a given pharmaceutical to Israel by a number
of importers—not necessarily directly from the manufacturer,
thus amplifying economic competition, which should result in
lower acquisition price. OBJECTIVES: Our study examines the
impact of the law three years after its implementation, regard-
ing the national expenditure on pharmaceuticals. METHODS:
Since ﬁnancial data is not available to the public, the study was
based on qualitative data. A survey of senior management of the
Israeli health care system was conducted. A pool of 50 execu-
tives was constructed, representing all relevant stakeholders.
Each participant was interviewed face-to-face, using a uniform
questionnaire. RESULTS: The response rate was 68%, all sectors
had at least one representative. The preliminary analysis of the
answers shows that although during 3 years, only 22 drugs were
parallel imported, most of the responders answered that both 
the national expenditure and prices of pharmaceuticals were
reduced. No damage was done to the publics’ health, and there
was no change in the number of newly approved pharmaceuti-
cals. CONCLUSIONS: As a result of the Parallel Import legis-
lation, combined with several other cost-containment reforms, a
reduction in the prices of pharmaceuticals is noticed. The fact
that only 22 pharmaceuticals, and none during 2003, were actu-
ally imported by parallel trade shows that the main reduction is
attributed to lower prices established by the manufacturers them-
selves, trying to avoid competition from parallel imports. Thus,
the importance of the law lies not necessarily by carrying it out,
but simply by the fact that it allows the major buyers to use it
as a tool in the negotiation with manufacturers.
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OBJECTIVE: Although drug manufacturers have gained com-
petence in pharmacoeconomic analysis, they have been slow to
bring these tools and techniques to bear on important “go/no-
go” decisions for compounds in development. This may be due
to difﬁculties in modeling the cost-effectiveness of products that
have yet to undergo clinical trials, wherein critical data on
important model parameters would be collected. Yet, in the
current cost-conscious environment, it is risky to invest in the
development of a product without ﬁrst exploring its potential
pharmacoeconomic proﬁle. METHOD: We developed an ana-
lytic apparatus for use in conjunction with traditional cost-
effectiveness models to illustrate how good a developmental
compound would need to be in terms of key clinical parameters
(e.g., adverse event rate, failure rate) for it to be cost-effective
versus competing products. Borrowing constructs from micro-
economic theory, we demonstrate how two-way threshold analy-
